Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
暂无分享,去创建一个
S. Horwitz | J. Boni | A. Spira | T. Menne | M. Fanale | P. Fields | A. Moskowitz | G. Collins | M. Hamadani | A. Karnad | J. Feingold | C. Hildyard | Shui He